Literature DB >> 23109371

Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.

Katherine B Gibney1, Srilatha Edupuganti, Amanda J Panella, Olga I Kosoy, Mark J Delorey, Robert S Lanciotti, Mark J Mulligan, Marc Fischer, J Erin Staples.   

Abstract

The duration of anti-yellow fever (YF) virus immunoglobulin M (IgM) antibodies following YF vaccination is unknown, making it difficult to interpret positive IgM antibody results in previously vaccinated travelers. We evaluated the frequency and predictors of YF IgM antibody positivity 3-4 years following YF vaccination. Twenty-nine (73%) of 40 participants had YF IgM antibodies 3-4 years postvaccination. No demographic or exposure variables were predictive of YF IgM positivity. However, persons who were YF IgM positive at 3-4 years postvaccination had earlier onset viremia and higher neutralizing antibody geometric mean titers at 1 month and 3-4 years postvaccination compared with persons who were YF IgM negative. Detection of YF IgM antibodies several years postvaccination might reflect remote YF vaccination rather than recent YF vaccination or YF virus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109371      PMCID: PMC3516084          DOI: 10.4269/ajtmh.2012.12-0182

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  Use of MAC-ELISA for evaluation of yellow fever vaccination.

Authors:  R M Nogueira; H G Schatzmayr; M P Miagostovich; S M Cavalcanti; R de Carvalho
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1992 Sep-Oct       Impact factor: 1.846

2.  Persistence of yellow fever vaccine RNA in urine.

Authors:  Miguel J Martínez; Anna Vilella; Tomás Pumarola; Montserrat Roldan; Victor G Sequera; Isabel Vera; Edward B Hayes
Journal:  Vaccine       Date:  2011-03-06       Impact factor: 3.641

3.  Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Erin Staples; Mark Gershman; Marc Fischer
Journal:  MMWR Recomm Rep       Date:  2010-07-30

4.  Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans.

Authors:  T P Monath
Journal:  Am J Epidemiol       Date:  1971-02       Impact factor: 4.897

5.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

6.  Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections.

Authors:  D A Martin; D A Muth; T Brown; A J Johnson; N Karabatsos; J T Roehrig
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

7.  Studies on serological cross-reaction in sequential flavivirus infections.

Authors:  Y Makino; M Tadano; M Saito; N Maneekarn; N Sittisombut; V Sirisanthana; B Poneprasert; T Fukunaga
Journal:  Microbiol Immunol       Date:  1994       Impact factor: 1.955

8.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

Authors:  Joseph D Miller; Robbert G van der Most; Rama S Akondy; John T Glidewell; Sophia Albott; David Masopust; Kaja Murali-Krishna; Patryce L Mahar; Srilatha Edupuganti; Susan Lalor; Stephanie Germon; Carlos Del Rio; Mark J Mulligan; Silvija I Staprans; John D Altman; Mark B Feinberg; Rafi Ahmed
Journal:  Immunity       Date:  2008-05-08       Impact factor: 31.745

9.  Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.

Authors:  Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

10.  Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies.

Authors:  Denis Malvy; Khaled Ezzedine; Maria Mamani-Matsuda; Brigitte Autran; Hugues Tolou; Marie-Catherine Receveur; Thierry Pistone; Jérome Rambert; Daniel Moynet; Djavad Mossalayi
Journal:  BMC Infect Dis       Date:  2009-12-10       Impact factor: 3.090

View more
  16 in total

Review 1.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 2.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

Review 3.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

4.  Evaluation of Whatman FTA cards for the preservation of yellow fever virus RNA for use in molecular diagnostics.

Authors:  Emily H Davis; Jason O Velez; Brandy J Russell; A Jane Basile; Aaron C Brault; Holly R Hughes
Journal:  PLoS Negl Trop Dis       Date:  2022-06-15

5.  Duration of West Nile Virus Immunoglobulin M Antibodies up to 81 Months Following West Nile Virus Disease Onset.

Authors:  J Erin Staples; Katherine B Gibney; Amanda J Panella; Harry E Prince; Alison J Basile; Janeen Laven; James J Sejvar; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2022-04-11       Impact factor: 3.707

6.  Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses.

Authors:  Tyler M Sharp; Marc Fischer; Jorge L Muñoz-Jordán; Gabriela Paz-Bailey; J Erin Staples; Christopher J Gregory; Stephen H Waterman
Journal:  MMWR Recomm Rep       Date:  2019-06-14

7.  Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study.

Authors:  Sam Proesmans; Freddy Katshongo; John Milambu; Blaise Fungula; Hypolite Muhindo Mavoko; Steve Ahuka-Mundeke; Raquel Inocêncio da Luz; Marjan Van Esbroeck; Kevin K Ariën; Lieselotte Cnops; Birgit De Smet; Pascal Lutumba; Jean-Pierre Van Geertruyden; Veerle Vanlerberghe
Journal:  PLoS Negl Trop Dis       Date:  2019-09-05

Review 8.  What Constitutes Protective Immunity Following Yellow Fever Vaccination?

Authors:  Jolynne Mokaya; Derick Kimathi; Teresa Lambe; George M Warimwe
Journal:  Vaccines (Basel)       Date:  2021-06-18

Review 9.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 10.  Yellow fever in the diagnostics laboratory.

Authors:  Cristina Domingo; Rémi N Charrel; Jonas Schmidt-Chanasit; Hervé Zeller; Chantal Reusken
Journal:  Emerg Microbes Infect       Date:  2018-07-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.